Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.
作者信息
Javitt Daniel C
机构信息
Experimental Therapeutics, Departments of Psychiatry and Neuroscience, Columbia University College of Physicians and Surgeons, 1051 Riverside Drive, Unit 21, New York, NY 10032.
出版信息
Curr Treat Options Psychiatry. 2015 Jun;1(2):107-120. doi: 10.1007/s40501-014-0010-9.
Abstract
摘要
相似文献
1
Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.
Curr Treat Options Psychiatry. 2015 Jun;1(2):107-120. doi: 10.1007/s40501-014-0010-9.
2
Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
Behav Brain Res. 2015 Feb 1;278:186-92. doi: 10.1016/j.bbr.2014.09.046. Epub 2014 Oct 6.
3
Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains.
J Clin Psychiatry. 2014;75 Suppl 1:21-6. doi: 10.4088/JCP.13049su1c.04.
4
Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis.
Curr Pharm Des. 2005;11(27):3561-94. doi: 10.2174/138161205774414538.
5
Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Int Rev Neurobiol. 2007;78:69-108. doi: 10.1016/S0074-7742(06)78003-5.
6
Glutamatergic drugs for schizophrenia.
Cochrane Database Syst Rev. 2006 Apr 19;2006(2):CD003730. doi: 10.1002/14651858.CD003730.pub2.
7
Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
Curr Pharm Des. 2015;21(26):3771-87. doi: 10.2174/1381612821666150724100952.
8
Atypical antipsychotics: mechanism of action.
Can J Psychiatry. 2002 Feb;47(1):27-38.
9
New Trends in the Treatment of Schizophrenia.
CNS Neurol Disord Drug Targets. 2017;16(8):900-906. doi: 10.2174/1871527316666170728165355.
10
Modulation of striatal dopamine release in vitro by agonists of the glycineB site of NMDA receptors; interaction with antipsychotics.
Eur J Pharmacol. 2005 Dec 19;527(1-3):52-9. doi: 10.1016/j.ejphar.2005.10.015. Epub 2005 Nov 22.
引用本文的文献
1
Iowa Gambling Task performance in individuals with schizophrenia: the role of general versus specific cognitive abilities.
Front Psychiatry. 2024 Dec 10;15:1454276. doi: 10.3389/fpsyt.2024.1454276. eCollection 2024.
2
Mismatch Negativity (MMN) as a Pharmacodynamic/Response Biomarker for NMDA Receptor and Excitatory/Inhibitory Imbalance-Targeted Treatments in Schizophrenia.
Adv Neurobiol. 2024;40:411-451. doi: 10.1007/978-3-031-69491-2_15.
3
Effective factors in the pathogenesis of .
Heliyon. 2024 May 19;10(10):e31558. doi: 10.1016/j.heliyon.2024.e31558. eCollection 2024 May 30.
4
Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry.
Neuropsychopharmacology. 2024 Jan;49(1):51-66. doi: 10.1038/s41386-023-01614-3. Epub 2023 Jun 27.
5
Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial.
Schizophr Bull. 2021 Jul 8;47(4):1108-1115. doi: 10.1093/schbul/sbab010.
6
Persistent negative symptoms in individuals at Ultra High Risk for psychosis.
Schizophr Res. 2019 Apr;206:355-361. doi: 10.1016/j.schres.2018.10.019. Epub 2018 Oct 26.
7
Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia.
Neuropsychopharmacology. 2018 Feb;43(3):571-582. doi: 10.1038/npp.2017.176. Epub 2017 Aug 17.
8
Septal Cholinergic Neuromodulation Tunes the Astrocyte-Dependent Gating of Hippocampal NMDA Receptors to Wakefulness.
Neuron. 2017 May 17;94(4):840-854.e7. doi: 10.1016/j.neuron.2017.04.021. Epub 2017 May 4.
9
The current conceptualization of negative symptoms in schizophrenia.
World Psychiatry. 2017 Feb;16(1):14-24. doi: 10.1002/wps.20385.
10
Time to Re-focus onto Cognitive Symptoms in Schizophrenia.
Indian J Psychol Med. 2016 Mar-Apr;38(2):93-6. doi: 10.4103/0253-7176.178765.
本文引用的文献
1
Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.
BMC Psychiatry. 2013 Dec 20;13:340. doi: 10.1186/1471-244X-13-340.
2
Cortical synaptic NMDA receptor deficits in α7 nicotinic acetylcholine receptor gene deletion models: implications for neuropsychiatric diseases.
Neurobiol Dis. 2014 Mar;63:129-40. doi: 10.1016/j.nbd.2013.11.021. Epub 2013 Dec 8.
3
Computerized cognitive training targeting brain plasticity in schizophrenia.
Prog Brain Res. 2013;207:301-26. doi: 10.1016/B978-0-444-63327-9.00011-4.
4
Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia.
Patient Prefer Adherence. 2013 Nov 13;7:1171-80. doi: 10.2147/PPA.S53795. eCollection 2013.
5
Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
J Clin Psychiatry. 2013 Oct;74(10):957-65. doi: 10.4088/JCP.13r08440.
6
Methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphism is associated with antipsychotic-induced weight gain in first-episode schizophrenia.
Int J Neuropsychopharmacol. 2014 Mar;17(3):485-90. doi: 10.1017/S1461145713001375. Epub 2013 Nov 13.
7
Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review.
Ann Gen Psychiatry. 2013 Oct 23;12(1):32. doi: 10.1186/1744-859X-12-32.
8
Atypical antipsychotics for psychosis in adolescents.
Cochrane Database Syst Rev. 2013 Oct 15;2013(10):CD009582. doi: 10.1002/14651858.CD009582.pub2.
9
α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia.
Annu Rev Med. 2014;65:245-61. doi: 10.1146/annurev-med-092112-142937. Epub 2013 Oct 9.
10
Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
JAMA Psychiatry. 2013 Dec;70(12):1267-75. doi: 10.1001/jamapsychiatry.2013.2159.
Zotero 插件